UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss including noncontrolling interests in subsidiaries	$ (92,360)	$ (54,142)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash used in operating activities:
Change in fair value of investment	0	2,752
Gain on sale of investment	0	(3,591)
Depreciation and amortization	10,140	7,198
Amortization of debt discount and issuance costs	90	1
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	3,941	14,683
Change in fair value of Series A warrants	(1,895)	11,887
Change in fair value of Series B warrants	(36,636)	177,296
Compensation expense for share-based awards	3,288	1,279
Loss on foreign currency exchange	4,530	193
Change in fair value of equity securities	266,202	(115,509)
Gain on sale of equity securities	(114,434)	(53,124)
Earnings on equity investment in joint venture	(42,935)	(2,737)
Deferred income taxes	(15,971)	0
Changes in assets and liabilities:
Accounts receivable	2,242	94
Inventories	(4,872)	0
Prepaid expenses and other assets	(1,078)	(2,191)
Accounts payable and accrued expenses	4,984	7,002
Royalties and contingent legal fees payable	795	(369)
Deferred revenue	371	0
Net cash used in operating activities	(13,598)	(9,278)
Cash flows from investing activities:
Patent acquisition	(5,000)	(13,000)
Sale of investment at fair value	0	3,591
Purchases of equity securities	(107,537)	(57,978)
Sales of equity securities	236,164	64,235
Distributions received from equity investment in joint venture	1,178	1,830
Purchases of property and equipment	(552)	(67)
Net cash provided by (used in) investing activities	124,253	(1,389)
Cash flows from financing activities:
Repurchase of common stock	(50,988)	0
Issuance of Senior Secured Notes, net of lender fee	0	115,000
Paydown of Senior Secured Notes	(120,000)	(50,000)
Dividend on Series A Redeemable Convertible Preferred Stock	(2,099)	(785)
Taxes paid related to net share settlement of share-based awards	(1,520)	0
Proceeds from exercise of stock options	0	202
Net cash (used in) provided by financing activities	(174,607)	64,417
Effect of exchange rates on cash and cash equivalents	(3,535)	(154)
(Decrease) increase in cash and cash equivalents and restricted cash	(67,487)	53,596
Cash and cash equivalents and restricted cash, beginning	309,361	200,546
Cash and cash equivalents and restricted cash, ending	241,874	254,142
Supplemental schedule of cash flow information:
Interest paid	5,431	2,340
Income taxes paid	209	9
Noncash investing and financing activities:
Patent acquisition in exchange of notes receivable	0	4,000
Patent acquisition accrued liabilities	0	13,000
Distribution to noncontrolling interests in subsidiaries	$ 586	$ 906